The effect of bisphosphonates and receptor activator of nuclear factor kappa-B ligand inhibitors on bone health provides an opportunity to decrease the incidence of skeletal-related events and improve cancer outcomes in certain subsets of patients.
Keyphrases
- nuclear factor
- toll like receptor
- early stage
- end stage renal disease
- bone mineral density
- ejection fraction
- healthcare
- newly diagnosed
- public health
- mental health
- risk factors
- bone loss
- soft tissue
- type diabetes
- childhood cancer
- weight loss
- radiation therapy
- health information
- peripheral blood
- bone regeneration
- human health
- skeletal muscle
- locally advanced
- sentinel lymph node
- rectal cancer